FIND, Geneva, Switzerland.
University Hospital Heidelberg, Division of Tropical Medicine, Centre of Infectious Diseases, Germany.
J Infect Dis. 2019 Oct 8;220(220 Suppl 3):S91-S98. doi: 10.1093/infdis/jiz097.
Existing high-priority target product profiles (TPPs) of the World Health Organization (WHO) establish important needs for tuberculosis (TB) diagnostic development. Building on this earlier work, this guidance series aims to provide study guidance for performing accuracy studies of novel diagnostic products that may meet the 4 high-priority WHO TPPs and thus enable adequate evidence generation to inform a WHO evidence review process. Diagnostic accuracy studies represent a fundamental step in the validation of all tests. Unfortunately, such studies often have limitations in design, execution, and reporting, leading to low certainty of the evidence about true test performance, which can delay or impede policy and scale-up decisions. This introductory paper outlines the following: (1) the purpose of this series of papers on study guidance; (2) WHO evidence needs and process for the development of policy guidelines for new TB diagnostic tests; and (3) study design considerations, ie, general diagnostic study considerations, intended use of test and role in the clinical pathway, choice of population and setting, index-test specific issues, suitable reference standard and comparators, study flow and specimen issues, and finally key issues beyond accuracy that should be considered. The other 4 papers in this series will provide more detailed guidance for each of the 4 WHO high-priority TPPs. By increasing the clarity around the clinical evaluation needs for tests that have the potential to meet the TPP specifications, we hope to support harmonized evidence generation and enable the WHO review process towards meeting the WHO End TB Strategy targets for reducing the incidence and mortality associated with TB.
现有的世界卫生组织(WHO)高优先级目标产品概况(TPP)确定了结核病(TB)诊断开发的重要需求。本指南系列在此早期工作的基础上,旨在为新型诊断产品的准确性研究提供研究指导,这些产品可能符合 4 项 WHO 高优先级 TPP,从而能够生成足够的证据来为 WHO 证据审查过程提供信息。诊断准确性研究是所有测试验证的基本步骤。不幸的是,此类研究在设计、执行和报告方面常常存在局限性,导致对真实测试性能的证据的确定性较低,这可能会延迟或阻碍政策和扩大规模的决策。本介绍性文件概述如下:(1)本关于研究指导的论文系列的目的;(2)WHO 对新的 TB 诊断测试的政策指南开发的证据需求和流程;(3)研究设计注意事项,即一般诊断研究注意事项、测试的预期用途及其在临床途径中的作用、人群和环境的选择、指标测试的具体问题、合适的参考标准和对照物、研究流程和标本问题,最后是除准确性之外还应考虑的关键问题。本系列中的其他 4 篇论文将为 4 项 WHO 高优先级 TPP 中的每一项提供更详细的指导。通过增加对有潜力满足 TPP 规范的测试的临床评估需求的清晰度,我们希望支持协调一致的证据生成,并使 WHO 审查过程能够达到降低与结核病相关的发病率和死亡率的 WHO 终止结核病战略目标。